Mergers and acquisitions in the pharmace
โ
Patricia M. Danzon; Andrew Epstein; Sean Nicholson
๐
Article
๐
2007
๐
John Wiley and Sons
๐
English
โ 237 KB
## Abstract We examine the determinants and effects of M&A activity in the pharmaceutical/biotechnology industry using SDC data on 383 firms from 1988 to 2001. For large firms, mergers are a response to expected excess capacity due to patent expirations and gaps in a firm's product pipeline. For sm